Throughout the last three months, 4 analysts have evaluated Collegium Pharmaceutical COLL, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 1 | 1 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Collegium Pharmaceutical, revealing an average target of $39.5, a high estimate of $40.00, and a low estimate of $39.00. Surpassing the previous average price target of $37.67, the current average has increased by 4.86%.
Interpreting Analyst Ratings: A Closer Look
The standing of Collegium Pharmaceutical among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| David Amsellem | Piper Sandler | Maintains | Neutral | $39.00 | $39.00 |
| Serge Belanger | Needham | Maintains | Buy | $40.00 | - |
| Les Sulewski | Truist Securities | Raises | Buy | $40.00 | $37.00 |
| David Amsellem | Piper Sandler | Raises | Overweight | $39.00 | $37.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Collegium Pharmaceutical. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Collegium Pharmaceutical compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Collegium Pharmaceutical's stock. This examination reveals shifts in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Collegium Pharmaceutical's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Collegium Pharmaceutical analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Discovering Collegium Pharmaceutical: A Closer Look
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Unraveling the Financial Story of Collegium Pharmaceutical
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Over the 3 months period, Collegium Pharmaceutical showcased positive performance, achieving a revenue growth rate of 15.53% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 21.33%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 17.07%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Collegium Pharmaceutical's ROA stands out, surpassing industry averages. With an impressive ROA of 2.75%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Collegium Pharmaceutical's debt-to-equity ratio stands notably higher than the industry average, reaching 3.45. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Analyst Ratings: Simplified
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
